Amsterdam deemed a good choice as EMA’s new home, but transition will not be easy

Monday, December 4, 2017

The EMA, a multi-national regulatory agency that serves more than 500 million people living in Europe, will relocate from London to Amsterdam as a direct result of Britain’s vote to leave the European Union (EU), known as Brexit. While the move will be devastating for Britain’s pharmaceutical and health sciences industries, it will bring nearly 1,000 new jobs and an injection of capital to Amsterdam, which will become the EMA’s new home when the U.K. officially leaves the EU in March 2019. Overall, 19 European cities bid on the highly sought-after spot. After a complex voting process, a tie-breaking draw of lots crowned Amsterdam the winner over Milan. 

[Read More]

QuintilesIMS is now IQVIA

Monday, November 6, 2017

QuintilesIMS will be changing its name to IQVIA, a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Beginning on November 15, 2017, equity shares of the company will trade on the NYSE under the new name and new ticker symbol “IQV.” Until then, IQVIA will continue to be listed under QuintilesIMS and symbol “Q” per the listing notification requirements of the NYSE. 

[Read More]

New evidence extends validation for quality review

Monday, October 2, 2017

The Good ReseArch for Comparative Effectiveness (GRACE) checklist is a simple 11-item tool that considers the study purpose and provides questions to guide high-level evaluation of methods, data quality and analytics for use in health technology assessments of effectiveness and safety studies. It provides a scoring tool to help evaluate studies in the context of the study goal, and can be used by sophisticated and less experienced users.

[Read More]

Is eConsent adoption poised to grow?

Friday, September 1, 2017

Activity in the eConsent sector has risen considerably during the past six months, with Medidata’s acquisition of electronic informed consent pioneer Mytrus and the entry of new market players, even though widespread industry adoption of the technology has appeared to have stalled.

[Read More]

Colleen Goggins joins QuintilesIMS Board of Directors

Thursday, July 27, 2017

QuintilesIMS, a provider of information, technology solutions and contract research services to the life sciences industry, announced the appointment of Colleen Goggins to its board of directors, effective today. A senior executive at Johnson & Johnson for more than three decades, Goggins retired in 2011 after serving ten years on J&J’s Executive Committee and as the Worldwide Chairman of its Consumer Group. Under her leadership, the J&J global personal and healthcare portfolio, comprising many of the most recognized consumer brands and medicines in the world, grew to more than $16 billion in annual revenue.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]